In the last trading session, 1.04 million shares of the Verrica Pharmaceuticals Inc (NASDAQ:VRCA) were traded, and its beta was 1.43. Most recently the company’s share price was $0.68, and it changed around $0.03 or 5.49% from the last close, which brings the market valuation of the company to $65.37M. VRCA currently trades at a discount to its 52-week high of $11.41, offering almost -1577.94% off that amount. The share price’s 52-week low was $0.61, which indicates that the current value has risen by an impressive 10.29% since then. We note from Verrica Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.77 million shares, with the 3-month average coming to 921.25K.
Verrica Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.60. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 4 recommended VRCA as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Verrica Pharmaceuticals Inc is expected to report earnings per share of -0.28 for the current quarter.
Verrica Pharmaceuticals Inc (NASDAQ:VRCA) trade information
Instantly VRCA has showed a green trend with a performance of 5.49% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.7381 on recent trading dayincreased the stock’s daily price by 7.87%. The company’s shares are currently down -90.65% year-to-date, but still up 1.18% over the last five days. On the other hand, Verrica Pharmaceuticals Inc (NASDAQ:VRCA) is -38.35% down in the 30-day period. We can see from the shorts that 2.0 million shares have been sold at a short interest cover period of 2.74 day(s).
The consensus price target as assigned by Wall Street analysts is $12, which translates to bulls needing to increase their stock price by 94.33% from its current value. Analyst projections state that VRCA is forecast to be at a low of $10 and a high of $14.
Verrica Pharmaceuticals Inc (VRCA) estimates and forecasts
Verrica Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -90.61 percent over the past six months and at a -24.56% annual growth rate that is well below the industry average of 16.60%. The year-over-year growth rate is expected to be 51.13%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 710.33k in revenue for the current quarter. 2 analysts expect Verrica Pharmaceuticals Inc to make 2.11M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.99M and 3.83M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -64.27%. Forecasts for the next quarter put sales growth at -44.89%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -0.97%.
VRCA Dividends
Verrica Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in January.
Verrica Pharmaceuticals Inc (NASDAQ:VRCA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 43.85% of Verrica Pharmaceuticals Inc shares, and 15.80% of them are in the hands of institutional investors. The stock currently has a share float of 28.14%. Verrica Pharmaceuticals Inc stock is held by 99.0 institutions, with PERCEPTIVE ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 15.2724% of the shares, which is about 7.1 million shares worth $51.75 million.
AVORO CAPITAL ADVISORS LLC, with 8.6052% or 4.0 million shares worth $29.16 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
